David Chang, PhD
Hematology & Oncology · Newport News, VANPI 1982718078
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $107,674 of the $141,499 with a category attached, or 76.1%. AstraZeneca accounts for 64.6% of it on its own, with 25 other manufacturers making up the rest. 2025 is the largest year on record at $65,028, more than ten times the $310 reported in 2019. Among hematology & oncology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 119 payments — averaging $1189.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$91K
- Beone Medicines USA, Inc.$13K
- Exelixis Inc.$7K
- Taiho Oncology, Inc.$6K
- Takeda Pharmaceuticals U.S.A., Inc.$5K
- Bayer$4K
- plus $15K from 20 others
Across 93 payments — averaging $11,119 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$485K
- E.r. Squibb & Sons, L.L.C.$288K
- Bayer$239K
- Ipsen Bioscience Inc.$20K
- Seagen Inc.$2K
- AstraZeneca$1K
- plus $38 from 1 others
What the payments were for
- Consulting fees$24,50617%
- Speaking & faculty fees$107,67476%
- Travel & lodging$5,6114%
- Food & beverage$3,5813%
- Education$1270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 59 | $91,457 |
| Beone Medicines USA, Inc. | 7 | $12,884 |
| Exelixis Inc. | 12 | $7,172 |
| Taiho Oncology, Inc. | 3 | $5,763 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $5,198 |
| Bayer | 3 | $4,196 |
| G1 Therapeutics, Inc. | 2 | $3,000 |
| Beigene USA, Inc. | 7 | $2,186 |
| Ipsen Biopharmaceuticals, Inc | 3 | $1,791 |
| Karyopharm Therapeutics Inc. | 1 | $1,550 |
| Incyte Corporation | 2 | $1,461 |
| Seagen Inc. | 1 | $1,375 |
| Coherus Oncology, Inc. | 1 | $1,350 |
| Amgen | 1 | $1,029 |
| Conmed Corporation | 3 | $189 |
| Eisai Inc. | 2 | $170 |
| Array Biopharma Inc | 1 | $150 |
| E.r. Squibb & Sons, L.L.C. | 1 | $118 |
| EMD Serono, Inc. | 1 | $106 |
| Medtronic | 1 | $105 |
| Sanofi-aventis U.S. LLC | 1 | $99 |
| Chiesi USA, Inc. | 1 | $84 |
| SPR Therapeutics, Inc | 1 | $35 |
| AbbVie | 1 | $18 |
| Gilead | 1 | $12 |
| Pfizer | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$141,499 in reported general payments places this provider in the 95th percentile of 293 hematology & oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 27 | $516,057 |
| FruzaqlaFruquintinib | 17 | $396,480 |
| ImbruvicaIbrutinib | 12 | $209,980 |
| Pazopanib Hcl | 16 | $136,344 |
| XareltoRivaroxaban | 52 | $35,850 |
| CreonLipase/Protease/Amylase | 13 | $18,030 |
| EliquisApixaban | 23 | $14,972 |
| Enoxaparin Sodium | 14 | $7,512 |
| Imatinib Mesylate | 14 | $7,035 |
| Letrozole | 50 | $1,717 |
| Megestrol Acetate | 12 | $1,319 |
| Ondansetron Hcl | 28 | $882 |
| Sodium Chloride0.9 % Sodium Chloride | 15 | $690 |
| Dexamethasone | 38 | $615 |
| Ondansetron OdtOndansetron | 21 | $524 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Fruzaqla | $5,198 | $396,48017 claims |
| AbbVieCreon | $18 | $18,03013 claims |
| PfizerEliquis | $4 | $14,97223 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 293 hematology & oncology providers in Virginia.
Other hematology & oncology in Newport News
- Ruby KochharHampton$236K
- Victor YazbeckRichmond$190K
- William ErshlerFairfax$139K
- Yue ZhangVirginia Beach$105K
- Jerome GoldschmidtChristiansburg$105K
- Attique SamdaniRichmond$104K
- Gary SimmonsNorfolk$82K
- Mark FlemingHampton$71K
- Sekwon JangFairfax$56K
- Craig PortellCharlottesville$48K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.